Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LTC004 in Advanced Malignancies
NCT05666635Phase 1Unknown
- Sponsor
- Leto Laboratories
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, open-label, single-arm trial of LTC004 in solid tumor (advanced stage) and lymphoma, sponsored by Leto Laboratories. Primary endpoints: Number of Participants with Adverse Event up to 12 months and Number of participants with Dose Limiting Toxicities up to 21 days. Status: unknown.
02
Drugs
LTC004
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05666635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666635.